Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Freiburger Medizintechnik Gmbh |
| Country | Germany |
| Start Date | Oct 01, 2022 |
| End Date | Sep 30, 2025 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190173644 |
Regular dental check-ups and treatments not only ensure a beautiful smile, but good general health: a healthy oral cavity strengthens the immune system and acts as a barrier against various heart-, kidney-, or lungs-related diseases and diabetes. There is currently no effective solution to treat the 16.3 mn infected dental implants (EU, 2019).
Freiburger Medizintechnik GmbH developed the solution dentists are looking for: a disruptive technology for highly effective infection control to fight periimplantitis.
AmbiJet® is the world’s first and only plasma-based technology with the ability to kill bacteria on dental implants in-situ.
It disrupts the status-quo of medical technologies by preventing the reinfection of disinfected surfaces and shows maximum effectiveness without side nor adverse effects: pharmacological and chemical substances are no longer required. AmbiJet® reduces inflammation, saves dental implants and helps patients live a healthier life.
Freiburger Medizintechnik Gmbh
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant